Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) projects Cur18™ will generate over $2.5 million in incremental annual U.S. revenue within 12–18 months based on its current commercialization strategy and internal assumptions. Cur18™ is a curcumin-based nutraceutical in the company’s 18 Series, planned initially for DTC e-commerce with potential retail expansion.
The projection depends on execution of pricing, sales volumes, and distribution expansion.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – COSM
On the day this news was published, COSM gained 2.49%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.6% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $494K to the company's valuation, bringing the market cap to $20.32M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While COSM was down 3.43%, peers like SNYR (-12.81%) and YI (-1.02%) also declined, and momentum data flags 2 peers moving down together (median about -6.0%), pointing to broader sector weakness.
Previous Crypto Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 17 | Product launch | Positive | +0.1% | Announcement of Q2 2026 U.S. launch for Cur18 next-gen curcumin supplement. |
| Apr 13 | Purchase order | Positive | +8.5% | Third Pharmalink order lifts cumulative Sky Premium Life units to 270,000. |
| Apr 10 | Operational update | Positive | +3.5% | Conflict impact minimal; record revenue and strong NOOR collagen outlook. |
| Apr 08 | Product launch | Positive | +0.6% | Planned Q2 launch of Liv18 liver supplement targeting $4.6B U.S. market. |
| Apr 01 | Clinical validation | Positive | +0.6% | C-Scrub Wash 4% passes EN 12791 surgical hand disinfection standard testing. |
Recent crypto-tag news has generally seen small but consistently positive next-day moves following operational and product expansion updates.
Over recent weeks, Cosmos has issued multiple crypto-tagged updates highlighting product launches, clinical validation, and commercial traction. Events include Q2 U.S. launches for Liv18 and Cur18, successful EN 12791 testing for C‑Scrub Wash 4%, and growing international orders for Sky Premium Life. These developments frame today’s Cur18 revenue projection as another step in expanding Cosmos’s nutraceutical and clinical-grade portfolio in key markets.
Historical Comparison
Past crypto-tag updates for COSM have produced an average next-day move of 2.64%, mainly on product launches and clinical validations, and today’s Cur18 revenue projection fits this ongoing commercialization narrative.
Crypto-tag history shows a steady build-out of Cosmos’s portfolio: validation of C-Scrub, planned Q2 launches of Liv18 and Cur18, growing NOOR collagen revenue projections, and expanding Sky Premium Life orders in new geographies.
Regulatory & Risk Context
An effective shelf registration on Form S-3/A filed April 24, 2026 covers registration of 73,523,716 common shares for resale, tied to convertible notes at a $0.176 floor price. The filing states selling stockholders, not the company, would receive proceeds from any resales.
Market Pulse Summary
This announcement adds quantified expectations to Cosmos’s U.S. nutraceutical push, projecting Cur18 to generate over $2.5 million in incremental annual revenue within 12–18 months. It follows earlier launches and revenue targets for Liv18 and NOOR, suggesting a broader branded portfolio build-out. Investors may monitor execution of the phased e-commerce strategy, uptake in the competitive turmeric/curcumin category, and implications of the recent S-3/A resale registration.
Key Terms
nutraceutical medical
curcumin medical
pharmacokinetic medical
AI-generated analysis. Not financial advice.
CHICAGO, IL / ACCESS Newswire / April 30, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it is projecting Cur18™ to generate over
Cur18™ is part of the Company's recently introduced "18 Series," a portfolio of science-based nutraceutical products. It is a curcumin-based dietary supplement formulated with a proprietary ingredient that has been evaluated in published pharmacokinetic and clinical studies and is positioned within the U.S. turmeric/curcumin supplement category.
The Company's projection reflects a phased market entry strategy, initially focused on direct-to-consumer e-commerce channels, with potential expansion into selected retail channels over time. It is based on internal assumptions regarding pricing, expected sales volumes, and the gradual expansion of distribution, and is subject to the continued execution of the Company's commercialization strategy.
Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "Cur18™ represents an important step in the commercialization of our 18 Series in the United States. Our focus is disciplined execution - entering a large and established category with a clearly positioned, science-supported product. The projected revenue reflects our current expectations based on our commercialization plans, and we believe Cur18™ has the potential to become a meaningful contributor to our broader nutraceutical portfolio as we scale distribution."
About Cosmos Health Inc.
Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire